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Background: Evidence has been provided that high-dose indacaterol (300 mg) can reduce lung
hyperinflation in moderate-to-severe chronic obstructive pulmonary disease (COPD).
Aim: To study whether low-dose indacaterol (150 mg) also reduces lung hyperinflation in
comparison with the recommended dose of tiotropium (18 mg) in moderate COPD.
Methods: This was a multicenter, randomized, blinded, 3-period cross-over, placebo-
controlled study. Spirometry and lung volumes were measured before and 30, 60, 120, 180
and 240 min after the administration of single-doses of indacaterol, tiotropium, or placebo.
The primary end-point was the change in peak inspiratory capacity (IC). The area under the
4-h curve (AUC0e4) for IC, 1-s forced expiratory volume (FEV1) and forced vital capacity
(FVC) were secondary variables.
Results: 49 patients completed the study. On average, peak IC and AUC0e4 for IC were signif-
icantly greater after indacaterol than placebo by 177 mL (pZ 0.007) and 142 mL (pZ 0.001),
respectively. Differences in peak IC and AUC0e4 for IC between tiotropium and placebo were
120 mL (p Z 0.07) and 85 mL (p Z 0.052), respectively. Differences between indacaterol
and tiotropium were statistically insignificant. Peak IC increased by >20% in 12 patients with
indacaterol and 9 with tiotropium (p Z 0.001), and by >30% in 8 patients with indacateroltive pulmonary disease; LABA, long-acting beta-agonist.
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A comparison with tiotropium 85and 3 with tiotropium (pZ 0.001). The effects of indacaterol and tiotropium on FEV1 and FVC
were statistically significant vs placebo.
Conclusions: Low-dose indacaterol has a bronchodilator effect that is similar to the recom-
mended dose of tiotropium, but it is slightly superior in reducing lung hyperinflation.
Trial registration: ClinicalTrials.gov number: NCT00999908.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
Long-acting bronchodilators are central to the management
of chronic obstructive pulmonary disease (COPD).1,2 Several
clinical trials have shown that sustained bronchodilatation
is associated with improvements in the so-called patient-
centered outcomes, namely, symptoms, exacerbations,
exercise tolerance and health status. These effects were
obtained with either long-acting b2-agonists (LABA)
3e6 or
the muscarinic antagonist, tiotropium.7e9 However, when
directly compared with LABA, tiotropium showed some
superiority,9 which was attributed to its longer duration of
action, i.e., 24 vs 12 h.
Indacaterol is a new LABA with a 24-h bronchodilator
effect (Ultra-LABA), which proved to be superior to both
formoterol and salmeterol based on measurements of 1-s
forced expiratory volume (FEV1).
10e13 However, FEV1 is
poorly correlated with symptoms and exercise intoler-
ance,14e15 which is more likely determined by dynamic
pulmonary hyperinflation in COPD.16e18 Indeed, a reduction
of pulmonary hyperinflation, as reflected by an increase in
inspiratory capacity (IC), has been shown to occur in
moderate-to-severe COPD patients treated with either
salmeterol19 or tiotropium,20,21 and this was consistently
associated with a reduction in dyspnea and an increase in
exercise tolerance. In a recent study, Beier and
colleagues22 found that high-dose indacaterol (300 mg)
caused a significantly larger increase in IC than the rec-
ommended dose of formoterol.
The present study was designed to investigate whether
the lower available dose of indacaterol (150 mg) can also
reduce pulmonary hyperinflation in comparison with either
placebo or the recommended dose of tiotropium (18 mg),
the other available once-daily bronchodilator, in patients
with moderate COPD.
Methods
The study protocol was approved by the Ethics Authority of
each participating center. Written informed consent was
obtained from each patient before entering the study.
Patient characteristics
All patients were at least 40 years old with a  10 pack-year
smoking history. They were required to have a clinical
diagnosis of COPD confirmed by post-bronchodilator (sal-
butamol 4  100 mg) FEV1/FVC <0.71 and FEV1/VC below
the lower limit of normality.23 Based on FEV1, they had to
be classified as moderate, i.e., GOLD stage II.1 Patientswere not included if they had a history of asthma or other
allergic diseases, an elevated blood eosinophil count, or
a recent respiratory tract infection.
Study design
This was a multicenter, randomized, single blinded, single
dose, 3-period cross-over (Latin-square design), placebo-
controlled study. Seven Pulmonary Units from University/
General Hospitals participated in the study by recruiting
patients from their outpatient clinics. At the first visit,
patients were screened for eligibility to take part in the
study. Those who met the inclusion criteria were asked to
suspend any regular treatment with long-acting broncho-
dilators (tiotropium or LABA) and inhaled corticosteroids
for the duration of the study. Inhaled salbutamol was
allowed as rescue medication on demand (up to a maximum
of 8 puffs/day). After seven days, patients had a second
screening visit to assess whether they still met the inclusion
criteria and were still willing to participate in the study.
Those who were still eligible to take part in the study were
randomized to receive single-doses of indacaterol (150 mg),
tiotropium (18 mg) or placebo on three occasions, separated
by 5-day washout periods. All doses were inhaled between
08:00 and 10:00 h, a.m.
On each study day, lung volumes and spirometry were
measured before and again 30, 60, 120, 180 and 240 min
after the administration of trial treatments. Investigator
staff and persons performing assessments and data analysis
remained blind to the treatment sequence from the time of
randomization until database lock. Study drugs were
received by a designated person at each study site and kept
in a secured location to which only the designated
unblinded site personnel had access.
Lung function measurements
Lung volumes were measured by a constant-volume vari-
able-pressure body plethysmograph according to ATS/ERS
recommendations.24 After a few regular tidal breaths,
functional residual capacity (FRC) was measured by having
the patient panting against a closed shutter at a frequency
slightly <1 Hz. After the opening of the shutter and a few
quiet tidal breaths without disconnecting from the mouth-
piece, the patient fully inspired to total lung capacity (TLC)
and IC was measured as the difference between TLC and
FRC. Measurements were taken in triplicate and the
average values of FRC and IC retained for analysis. Residual
volume was calculated as the difference between TLC and
the largest slow vital capacity (VC) from three acceptable
maneuvers. Forced expiratory maneuvers were then
Table 1 Patient characteristics.
Age (yr) 69  9
Sex (male/female) 45/4
Smoking habit (current/former) 13/36
BMI (Kg/m2) 27.4  4.6
VC (L) 3.18  0.71
IC (L) 2.33  0.54
FVC (L) 3.11  0.69
FEV1 (L) 1.81  0.40
FEV1 (% of predicted) 68.7  9.7
FEV1/FVC (%) 58.2  7.7
FRC (L) 4.97  1.16
FRC (% of predicted) 147.5  33.6
TLC (L) 7.32  1.52
TLC (% of predicted) 114.4  19.2
RV (L) 3.67  1.10
RV (% of predicted) 158.4  40.5
Data are  SD unless otherwise stated. All lung function data
are post-bronchodilator.
86 A. Rossi et al.obtained and analyzed according to the ATS/ERS recom-
mendations.25 The largest FEV1 and FVC from three
acceptable and repeatable maneuvers were taken, even if
they were not from the same curve.
Statistical analysis
The primary efficacy variable was the peak increase in IC
from pre-dose among the readings at 30, 60, 120, 180,
240 min post dose, and was summarized by sequence and
treatment for the per-protocol population. We calculate an
IC peak clinical difference of 65 ml with 80% power,
assuming a standard deviation of 170 ml, with a one-tailed
0.025 level of significance. Secondary variables were the
normalized area under the 4-h curve (AUC0e4) for IC, FEV1
and FVC, and the number of patients with peak IC incre-
ments exceeding predetermined thresholds, i.e., 10%, 20%
and 30%. Statistical significance was tested by analysis of
variance (ANOVA) with the following factors: treatment,
period, sequence and patient-within-sequence. Least
square means and associated standard errors were calcu-
lated for each treatment group as well as treatment
differences with 95% confidence intervals. Mc Nemar test
was used for categorical data. P < 0.05 was considered
statistically significant.
Results
Fifty-four out of 62 patients screened were randomized and
49 of them completed the study. The five withdrawals were
due to protocol violations (Fig. 1).
Their demographic and functional characteristics are
shown in Table 1.Random
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Figure 1 Study design and patient disposition of the 3-period cr34 patients had TLC>100% predicted; 43 patients had
FRC>110% predicted and 37 patients had RV>120% pre-
dicted. No significant difference was observed among
baseline values for any of the variables considered in the
study and treatment sequences. Before the study, 18% of
patients were not assuming any regular pharmacotherapy;
38% of them were on fixed dose LABA þ ICS combinations;
33% were on tiotropium, and 11% were on LABA
monotherapy.
Compared with placebo, the mean increments of peak IC
(Fig. 2) and AUC 0e4 for IC (Fig. 3) were significantly largerized
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oss-over sequences. A: indacaterol; B: tiotropium, C: placebo.
Figure 2 Difference in peak inspiratory capacity (IC). Data
are mean  95% CI. **p < 0.01 versus placebo.
Figure 4 Distribution of patients with significant improve-
ments in inspiratory capacity (IC) over 4 h. P-values denote
significant differences between indacaterol and tiotropium.
A comparison with tiotropium 87with indacaterol (by 177 mL, p Z 0.007 and 142 mL,
p Z 0.001, respectively). With tiotropium the mean
increments of peak IC and AUC 0e4 for IC tended to be larger
than after placebo without reaching the predetermined
level of statistical significance (by 120 mL, p Z 0.07 and
85 mL, p Z 0.052, respectively). Differences between
indacaterol and tiotropium in peak IC and AUC0.4 for IC
were not statistically significant (p Z 0.18 and p Z 0.38,
respectively).
The distribution of percent changes in peak IC from
baseline with indacaterol or tiotropium is shown in Fig. 4.
Peak IC increased by >10% in 27 patients with indacaterol
and 29 with tiotropium (p Z 0.06), by >20% in 12 patients
with indacaterol and 9 with tiotropium (p Z 0.001) and by
>30% in 8 patients with indacaterol and 3 with tiotropium
(p Z 0.001).
Both indacaterol and tiotropium increased the AUC0e4 of
FEV1 and FVC (Fig. 5) significantly compared with placebo
(p < 0.01), without significant differences between them.Pre-dose            30                    60                    120 180                  240
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Figure 3 Changes in inspiratory capacity (IC) from pre-dose
over 4 h after a single dose of indacaterol, tiotropium or
placebo. Data are mean  SE. Statistical differences in AUC0e4:
**p < 0.05 versus placebo; ##p < 0.05 versus placebo.The mean changes of FRC, RV, and TLC, at the 4th hour
after administration, are illustrated in Fig. 6.Discussion
The main findings of this study are that: 1) 150 mg of
indacaterol significantly increased IC in patients withFigure 5 Changes in FEV1 AUC (0-4) and FVC AUC (0e4) from
pre-dose over 4 h after a single dose of indacaterol, tiotropium
or placebo. A, Indacaterol vs placebo p < 0.02, tiotropium vs
placebo: p < 0.02, indacaterol vs tiotropium: p Z 0.6. B,
Indacaterol vs placebo p < 0.02, tiotropium vs placebo:
p < 0.02, indacaterol vs tiotropium p Z 0.4. Data are
expressed as mean  SE; Differences between treatments were
for all time-points.
Figure 6 Changes in FRC, TLC and RV at the 4th hours after administration.FRC was decreased compared to pre-dose by
305  100 ml with indacaterol (pZ 0.01) and by 236  88 ml with tiotropium (pZ 0.053); TCL by 152  0.114 ml with indacaterol
(p Z 0.208) and by 28  85 ml with tiotropium.(p Z 0.806); RV by 396  0.125 ml with indacaterol (p Z 0.004) and by
301  0.106 ml with tiotropium (p Z 0.029) Data are expressed as mean  SE.
88 A. Rossi et al.moderate COPD on the first day of administration and 2)
this effect was slightly superior to that of the recom-
mended dose of tiotropium, despite similar effects on FEV1
and FVC.
In patients with COPD, dynamic pulmonary hyperinfla-
tion is often present at rest.26 Since RV and FRC are
generally increased to a greater extent than TLC, the
inspiratory reserve available for increasing tidal volume is
reduced, which is considered to be a major mechanism for
reduced exercise tolerance in these patients. Breathing at
high lung volumes is associated with a remarkable increase
in the elastic work of breathing due not only to the greater
lung recoil, but also to the need of counterbalancing the
inward recoil of the chest wall. In fact, dyspnea, exercise
tolerance and health status are loosely correlated with
FEV1, which is the most popular index of airway caliber, but
better correlated with IC, which reflects lung hyper-
inflation.27e29 Therefore, it is desirable that measurements
of lung volumes are included when the effects of bron-
chodilators are to be assessed in COPD.30,31
In the present study we observed the effect of indaca-
terol and tiotropium during the first 4 h on the first day of
administration because both drugs resulted in peak effect
at 1.5e2 h with a mean FEV1 improvement. The lower
available dose of indacaterol (150 mg) caused increments of
both FVC and FEV1 that were not significantly different
from those caused by the recommended dose of tiotropium
(18 mg). Although both peak IC and AUC0e4 for IC were
greater after either indacaterol or tiotropium than after
placebo, these differences reached statistical significance
only with indacaterol.
Previous studies have shown that IC has a within-session
natural variability that is about 9% or 220 mL.25,32 There-
fore, we considered patients with an increase in IC>10% as
volume responders to bronchodilators. While no significant
difference was observed between indacaterol and tio-
tropium in the number of patients who showed a >10%
increase in IC, the number of patients with a larger (>20%
and >30%) improvement in IC was significantly greater with
indacaterol than tiotropium.
These results are unlikely to be due to differences in
baseline values, because there were no differences inbaseline lung function between treatment sequences.
Furthermore, our results cannot be due to differences in
the doses of the drugs, because the effects on FEV1 and FVC
were not significantly different.
There is a solid evidence showing potent bronchodilator
efficacy of indacaterol in COPD.10e13 Beier and colleagues22
have also shown that 300 mg indacaterol had a significantly
greater effect than formoterol on both FEV1 and IC. The
present study is the first one directly comparing the effects
of low-dose indacaterol with the marketed dose of tio-
tropium on lung hyperinflation. The decrease in RV, and
FRC appeared to be greater with indacaterol than with
tiotropium.
The majority of studies on indacaterol to date recruited
patients with moderate-to-severe COPD, i.e., with FEV1
<80% and >30% of the predicted value. The present study
was designed to include only patients with moderate COPD,
i.e., with FEV1 <80% and 50% of the predicted value. A
recent longitudinal study has shown that in this severity
group tiotropium may improve lung function and slightly
but significantly decrease the rate of decline of FEV1 over
a 4-year period.33 Therefore, patients with moderate COPD
are likely to experience substantial benefit from regular
therapy with long-acting bronchodilators.
A potential limitation may be that this study only
examined acute effects. By not examining effects of the
study drugs beyond a single day we might have under-
estimated the potential acute effect of both drugs because
of the delay in the achievement of a pharmacodynamic
steady state for these drugs. In addition we have only
examined the acute effects of the study drugs over the first
4 h. Hence we do not know whether the comparison might
have yielded the same results over the entire 24 h duration
of action.
We must mention that a previous study which compared
the acute effect of tiotropium versus a combination
therapy with single inhaler budesonide/formoterol on the
degree of resting pulmonary hyperinflation documented
that tiotropium is able to modify IC even after an acute
administration points out its capacity of influencing expi-
ratory flow limitation in a very fast manner.34 In a 12-week
study published recently, Buhl et al35 showed that
A comparison with tiotropium 89indacaterol 150 mcg and tiotropium 18 mcg had similar
effects on trough FEV1 but indacaterol was superior in
reducing dyspnea.
The results of the present study are encouraging for the
designing of longer and more complex studies. In this
regard, it is worth noting that even patients with mild COPD
(i.e., FEV1 >80% of the predicted value) have a reduced
exercise tolerance36 which can be improved by bronchodi-
latation.37 It has been suggested that patients with COPD
might receive additional benefit from regular treatment
with long-acting bronchodilators earlier in the course of
their diseases than was traditionally thought, and that both
airflow obstruction and lung hyperinflation should therefore
be targeted.38 Data from our study and those by Beier and
colleagues22 show that indacaterol is effective in improving
spirometry and decreasing pulmonary hyperinflation on the
first day of administration. Whether this rapid functional
improvement may influence patient compliance to the
treatment and patient-centered outcomes remains to be
established in long-term studies.39,40
The data of the present study also demonstrates that IC
may be a more sensitive measure than FEV1 in discrimi-
nating between the effects of indacaterol and tiotropium
on lung function in patients with moderate COPD.Conclusion
In summary, this study shows that the lower available dose
of the new ultra-long-acting bronchodilator, indacaterol,
acutely improved spirometry in a manner similar to the
recommended dose of tiotropium, but it was slightly
superior in reducing lung hyperinflation. Long-term studies
are necessary to evaluate whether this difference trans-
lates into greater beneficial effects on clinical end-points
such as exercise tolerance and dyspnea.Author contributions
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